Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury.
Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury.
复制标题
抑制covid -19介导的肺部和全身炎症和血管损伤的策略。
DOI：
10.1016/j.trsl.2020.12.008
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Garcia JGN
中科院分区：
文献类型：
--
作者：
Bime C;Casanova NG;Nikolich-Zugich J;Knox KS;Camp SM;Garcia JGN
大约15%-20%的感染SARS-CoV-2冠状病毒(新冠肺炎)的患者病情发展超过轻度和自限性疾病，严重肺炎需要补充氧气；5%的新冠肺炎感染患者进一步发展为急性呼吸窘迫综合征和多器官衰竭。尽管死亡率超过40%，但对新冠肺炎诱导的急性呼吸窘迫综合征的病理机制的关键见解尚未完全阐明，仍有多种需求未得到满足。这篇综述着重于针对未受抑制的先天性免疫驱动的炎症的有效治疗的需求尚未得到满足，该炎症导致未受控制的血管通透性、多器官功能障碍和ARDS死亡率。其他未得到满足的需求包括对预测致病性高炎性病毒宿主反应的因素缺乏洞察力，解决ARDS巨大疾病异质性的方法有限，以及缺乏临床上有用的ARDS生物标记物。我们回顾了在新冠肺炎诱导的急性呼吸窘迫综合征中持续存在的未得到满足的需求，在此背景下，肺损伤相关分子模式蛋白和系统性高炎性宿主对SARS-CoV-2感染的反应最终导致多器官功能障碍和急性呼吸窘迫综合征死亡率的潜在作用。对新冠肺炎和非COVID ARDS中有前景的分层增强、基于生物标记物的策略的洞察可能会使有前景的疗法的成功临床试验的设计成为可能。
Approximately 15%-20% of patients infected with SARS-CoV-2 coronavirus (COVID-19) progress beyond mild and self-limited disease to require supplemental oxygen for severe pneumonia; 5% of COVID-19-infected patients further develop acute respiratory distress syndrome (ARDS) and multiorgan failure. Despite mortality rates surpassing 40%, key insights into COVID-19-induced ARDS pathology have not been fully elucidated and multiple unmet needs remain. This review focuses on the unmet need for effective therapies that target unchecked innate immunity-driven inflammation which drives unchecked vascular permeability, multiorgan dysfunction and ARDS mortality. Additional unmet needs including the lack of insights into factors predicting pathogenic hyperinflammatory viral host responses, limited approaches to address the vast disease heterogeneity in ARDS, and the absence of clinically-useful ARDS biomarkers. We review unmet needs persisting in COVID-19-induced ARDS in the context of the potential role for damage-associated molecular pattern proteins in lung and systemic hyperinflammatory host responses to SARS-CoV-2 infection that ultimately drive multiorgan dysfunction and ARDS mortality. Insights into promising stratification-enhancing, biomarker-based strategies in COVID-19 and non-COVID ARDS may enable the design of successful clinical trials of promising therapies.
登录
查看更多内容
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
4.5
作者：
Biswas I;Khan GA
通讯作者：
Khan GA
影响因子：
76.2
作者：
Calfee, Carolyn S.;Delucchi, Kevin;Parsons, Polly E.;Thompson, B. Taylor;Ware, Lorraine B.;Matthay, Michael A.
通讯作者：
Matthay, Michael A.
影响因子：
2.6
作者：
Elangovan, Venkateswaran Ramamoorthi;Camp, Sara M.;Garcia, Joe G. N.
通讯作者：
Garcia, Joe G. N.
DOI：
10.1165/rcmb.2005-0404oc
发表时间：
2006-04-01
影响因子：
6.4
作者：
Gao, L;Grant, A;Garcia, JGN
通讯作者：
Garcia, JGN